NCT00812149 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR
Characterization of the 5'-flanking and 5'-untranslated regions of the cyclic adenosine 3',5'-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology. 2000 Jan;141(1):229-37.
Bianco AC, Kim BW
Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006 Oct;116(10):2571-9. Review.
Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR
Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002 Feb;23(1):38-89. Review.

Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers:The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3

Details for clinical trial NCT00812149

Clinical trial NCT00812149 - References